H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Inovio Pharmaceuticals (NASDAQ: INO) today and set a price target of $13. The company’s shares closed yesterday at $3.89, close to its 52-week low of $3.76.
Selvaraju wrote:
“We reiterate our Buy rating and $13 price target. PENNVAX-GP elicits robust, durable T cell and antibody response. We note that Inovio’s infectious disease platform has been validated in terms of high levels of both immune and antibody responses in multiple indications.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -1.9% and a 38.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Inovio Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $10.50, representing a 169.9% upside. In a report issued on June 21, Maxim Group also maintained a Buy rating on the stock with a $8 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $8.22 and a one-year low of $3.76. Currently, Inovio Pharmaceuticals has an average volume of 936.7K.
Based on the recent corporate insider activity of 21 insiders, corporate insider sentiment is negative on the stock. Most recently, in April 2018, Simon Benito, a Director at INO sold 3,750 shares for a total of $19,613.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Inovio Pharmaceuticals, Inc. engages in the development of active DNA immunotherapies for cancer and infectious diseases. Its portfolio of immune therapies includes SynCon immunotherapies and electroporation delivery systems. The company was founded on June 29, 1983 and is headquartered in Plymouth Meeting, PA.
